{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:34:56Z","timestamp":1789929296041,"version":"4.0.1"},"reference-count":95,"publisher":"Informa Healthcare","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2016,2,1]]},"DOI":"10.3111\/13696998.2015.1100115","type":"journal-article","created":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T21:07:32Z","timestamp":1443474452000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland"],"prefix":"10.3111","volume":"19","author":[{"given":"Thomas R.","family":"Einarson","sequence":"first","affiliation":[{"name":"aLeslie Dan Faculty of Pharmacy, University of Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Pudas","sequence":"additional","affiliation":[{"name":"bJanssen-Cilag, Espoo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpendra","family":"Goswami","sequence":"additional","affiliation":[{"name":"cJanssen-Cilag GmbH, Neuss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristel","family":"van Impe","sequence":"additional","affiliation":[{"name":"cJanssen-Cilag GmbH, Neuss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil G.","family":"Bereza","sequence":"additional","affiliation":[{"name":"dLeslie Dan Faculty of Pharmacy, University of Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3197","published-online":{"date-parts":[[2015,11,11]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0b013e318275d249"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a007078"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2005.00717.x"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-005-0853-x"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.841705"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1590\/S0034-89102010005000049"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.03.034"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1177\/2045125312474019"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-12-32"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S53795"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.771641"},{"key":"CIT0012","unstructured":"Abilify Maintena, aripiprazole Summary of product characteristics. London, UK: European Medicines Agency. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002755\/human_med_001711.jsp&mid=WC0b01ac058001d124. Accessed May 3, 2015"},{"key":"CIT0013","unstructured":"Zypadhera, olanzapine Summary of product characteristics. London, UK: European Medicines Agency. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000890\/human_med_001188.jsp&mid=WC0b01ac058001d124. Accessed May 3, 2015"},{"key":"CIT0014","unstructured":"Xeplion, paliperidone Summary of product characteristics. London, UK: European Medicines Agency. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002105\/human_med_001424.jsp&mid=WC0b01ac058001d124. Accessed May 3, 2015"},{"key":"CIT0015","unstructured":"Risperdal Consta (risperidone) Summary of product characteristics. London, UK: European Medicines Agency, 2007. London, UK: European Medicines Agency. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Risperdal_Consta_30\/WC500008168.pdf. Accessed May 3, 2015"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.823869"},{"key":"CIT0017","unstructured":"Ministry of Social Affairs and Health, Finland. Guidelines for preparing a health economic evaluation. http:\/\/www.ispor.org\/PEguidelines\/source\/GuidelinesinFinland_EnglishVersion.pdf. Helsinki, Finland, 2009. Accessed April 26, 2015"},{"key":"CIT0018","unstructured":"National Collaborating Centre for Mental Health. Schizophrenia: The NICE guidelines on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Updated edition. National Clinical Guideline Number 82. London, UK: National Institute for Health and Clinical Excellence, 2010."},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2003.10.010"},{"key":"CIT0020","first-page":"101","volume":"11","author":"Revicki DA","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"CIT0021","unstructured":"Abilify Maintena\u00ae summary of product characteristics. London, UK: European Medicines Agency, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002755\/WC500156111.pdf. Accessed May 3, 2015"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09168"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04421"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"CIT0025","unstructured":"Zypadhera Summary of product characteristics. London, UK: European Medicines Agency, 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000890\/WC500054429.pdf. Accessed May 5, 2015"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0512"},{"key":"CIT0027","unstructured":"Xeplion Summary of product characteristics. London, UK: European Medicines Agency, 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002105\/WC500103317.pdf. Accessed May 6, 2015"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.10.026"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32833948fa"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709990988"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.79"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181dd3103"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S54051"},{"key":"CIT0034","unstructured":"European Medicines Agency. Risperdal Consta_ summary of product characteristics. London, UK, 2008. characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Risperdal_Consta_30\/WC500008170.pdf. Accessed May 5, 2015"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.11.008"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.02.015"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000006"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2011.02.001"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-105"},{"key":"CIT0040","volume-title":"The use of olanzapine as a first and second choice treatment in schizophrenia. A West Midlands Development and Evaluation Committee Report","author":"Cummins C","year":"1998"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.05.014"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.3111\/200104137156"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07530"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0317"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.7.681"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2007.05.002"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0903"},{"key":"CIT0048","first-page":"171","volume":"28","author":"Fleischhacker WW1","year":"2013","journal-title":"Int Clin Psychopharmacol"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.1443"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.07081221"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.55.8.886"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2010.03.015"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/791468"},{"key":"CIT0054","unstructured":"Mehnert A, Diels J. Impact of administration interval on treatment retention with long-acting antipsychotics in schizophrenia. Presented at the Tenth Workshop on Costs and Assessment in Psychiatry -Mental Health Policy and Economics; Venice, Italy, 25-27 March 2011"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110372817"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711001076"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903149306"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S29052"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105056514"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1002\/hup.782"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2006.08.004"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200505000-00001"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2008.12.002"},{"key":"CIT0064","unstructured":"IMS Health Oy SLD price. Finland: Suomen L\u00e4\u00e4keData Oy. http:\/\/www.sld.fi\/finland.html. Accessed April 22, 2014"},{"key":"CIT0065","unstructured":"Price list: Kliinisen Kemian Laboratoriotutkimusten Ja Verivalmisteiden. Hinnasto 2015. Sein\u00e4joki, Finland: Etel\u00e4-Pohjanmaan sairaanhoitopiiri, January 1, 2015"},{"key":"CIT0066","unstructured":"Kapiainen S, V\u00e4is\u00e4nen A, Haula T. Terveyden- ja sosiaalihuolloin yksikk\u00f6kustannukset Suomessa vuonna 2011. Raportti 3\/2014. Terveyden ja hyvinvoinnin laitos. https:\/\/www.julkari.fi\/bitstream\/handle\/10024\/114683\/THL_RAPO3_2014_web.pdf?sequence=1. Tampere, Finland 2014. Accessed May 3, 2015"},{"key":"CIT0067","unstructured":"HUS Palveluhinnasto 2014. Osa 2 Suoriteperusteiset sairaanhoidolliset palvelut. http:\/\/www.hus.fi\/hus-tietoa\/talous\/Hinnoittelu\/Documents\/HUS%20Palveluhinnasto%202014%20OSA%202.pdf. Helsinki, Finland 2014 Accessed May 3, 2015"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"CIT0069","unstructured":"Triami Media BV. Inflation.eu website. http:\/\/www.inflation.eu\/inflation-rates\/finland\/historic-inflation\/cpi-inflation-finland-2015.aspx. Accessed May 3, 2015"},{"key":"CIT0070","unstructured":"European Central Bank. Euro foreign exchange reference rates. Frankfurt-am-Main, Germany, 2015. https:\/\/www.ecb.europa.eu\/stats\/exchange\/eurofxref\/html\/eurofxref-graph-gbp.en.html. Accessed July 14, 2015"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802490512"},{"key":"CIT0072","doi-asserted-by":"crossref","first-page":"A358","DOI":"10.1016\/S1098-3015(10)74761-6","volume":"12","author":"Carroll SM","year":"2009","journal-title":"Value Health"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.2165\/11536180-000000000-00000"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00344.x"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X253834"},{"issue":"1","key":"CIT0076","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00019053-200523001-00005","volume":"23","author":"Laux G","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200018060-00004"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.820193"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-11-18"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-5215.2012.00670.x"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.3109\/08039488.2013.852243"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.554533"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1186\/2045-4015-2-50"},{"key":"CIT0084","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2013.06.008"},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.681531"},{"key":"CIT0086","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-013-0050-0"},{"key":"CIT0087","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.917089"},{"key":"CIT0088","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0910"},{"key":"CIT0089","doi-asserted-by":"publisher","DOI":"10.3109\/08039488.2011.590603"},{"key":"CIT0090","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01431.x"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-7-16"},{"key":"CIT0092","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.02.008"},{"key":"CIT0093","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2008.07.033"},{"key":"CIT0094","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-9-35"},{"key":"CIT0095","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145703003651"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3111\/13696998.2015.1100115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T01:15:12Z","timestamp":1597454112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3111\/13696998.2015.1100115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,11]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2,1]]}},"alternative-id":["10.3111\/13696998.2015.1100115"],"URL":"https:\/\/doi.org\/10.3111\/13696998.2015.1100115","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}